NTRB News & Events

Nutriband signed an exclusive distribution agreement with Costa Rica Based Innomedica for AVERSA Fentanyl upon approval and all sports tape products manufactured at its Pocono Pharmaceutical / Active Intell subsidiary. Innomedica will also be overseeing and financing all regulatory approvals for the above mentioned products as they ramp up for launch.

Nutriband has provided an update to shareholders on the key milestones and discussions from this years Annual Shareholders Meeting. Addition of Two New Directors: Allesandro Puddu and Viorica Carlig added as two new directors. 2025 Aversa Fentanyl Development Summary: Strengthened collaboration with Kindeva through an exclusive product development partnership; Granted patent protecting its Aversa abuse deterrent platform technology in Macao; Completed commercial manufacturing process scale-up with partner Kindeva for Aversa Fentanyl; Issued new US patent which further expands Nutriband's intellectual property protection in the United States; Held Type C meeting with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for Aversa Fentanyl; Filed a new provisional patent application with the U.S. Patent and Trademark Office covering improved aversive formulations and coating application methods; Initiated development of the worldwide commercial brand name and visual identity for Aversa Fentanyl with Brand Institute. 2026 Aversa Fentanyl Focus on Development Towards NDA Filing: File nonprovisional patent application to potentially extend patent protection of Aversa technology-based products to 2046; Manufacture clinical supplies for the Human Abuse Liability clinical trial; File Investigational New Drug application with the US FDA; Initiate Human Abuse Liability clinical study. EarthVision Bio Purchase of Pocono Pharma: The full purchase price and closing for the proposed sale of our Pocono subsidiary has not been received as of the shareholder meeting on Jan 24, 2026. However, the Company is collecting on the agreed nonrefundable $10,000 USD weekly penalty and has so far collected $30,000 USD of payments to extend the closing date.

Nutriband announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2025 and the potential outlook for 2026. The letter read, in part, "As we wrapped up a successful 2025, the entire team at Nutriband would like to extend our warmest appreciation to all of you for your continued support throughout 2025 and into 2026. I always stress and extend our appreciation to the many of you that have been with us from the beginning and now the many more who have joined our common goal along the way. This goal is to change the world for the better by creating technology designed to improve the safety standard of easily abused transdermal drugs while simultaneously focusing on making these safer treatments available to patients who require them...This coming year we look forward to continuing to stride towards commercialization with AVERSA Fentanyl...Your continued support and belief in our vision have been pivotal to our reaching these milestones and others as we forge ahead. We remain committed to our shareholder value as our number one focus and as we near closer to commercialization for AVERSA product 1, I have no doubt that strategy will shine through."

Nutriband signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical for $5M to EarthVision Bio. Nutriband. Shareholders will retain 10% of the shareholding in Earth Vision Bio following the acquisition. Nutriband will use the proceeds from the sale of Pocono Pharma towards its continued development of AVERSA Fentanyl which has the potential to be the world's first and only abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches.